Search
Hengrui Medicine (600276.SH): Notification of Approval for Clinical Trial Initiation of HRS-6093 Tablets
2025-08-25 /
Read about 0 minute
Author：小编
Hengrui Medicine is pleased to announce that it has obtained approval from the National Medical Products Administration (NMPA) for the clinical trial of HRS-6093 Tablets. The company anticipates commencing these trials in the near future. HRS-6093 Tablets represent a groundbreaking oral KRASG12D inhibitor, uniquely designed to target and bind KRASG12D mutant proteins, thereby exerting potent anti-tumor effects. Notably, no comparable products have been approved for marketing either domestically or globally to date.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
